Abbott Abbokinase Use Should Be Limited Due To Infection Risks From Donors
Executive Summary
Abbott's Abbokinase should be limited to patients who specifically require the thrombolytic agent, FDA's Center for Biologics Evaluation & Research declared in a Jan. 25 letter to healthcare providers.
You may also be interested in...
Gabapentin ANDA Comparing Tabs To Caps Is Not Complete, Petition Says
An ANDA for gabapentin tablets that references Warner-Lambert's Neurontin capsules should be treated by the agency as "not substantially complete," an Aug. 12 citizen's petition to FDA argues.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011